Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.67 |
| ▸ | BCR | P11274 | 1/20 | 0.65 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21477626 | 1.00 | ABL1 (0.70) | ABL1KCNH2BCRCRBN | |
| Bromide SCHEMBL28902250 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| Bromide SCHEMBL30091102 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| Bromide SCHEMBL28902248 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| Hydrochloric Acid SCHEMBL28902253 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| Hydrochloric Acid SCHEMBL30091086 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| Hydrochloric Acid SCHEMBL28902254 | 0.99 | ABL1 (0.69) | ABL1KCNH2BCRCRBN | |
| SCHEMBL28902246 | 0.96 | ABL1 (0.66) | ABL1KCNH2BCRCRBN | |
| SCHEMBL30091177 | 0.96 | ABL1 (0.66) | ABL1KCNH2BCRCRBN | |
| SCHEMBL21477576 | 0.94 | ABL1 (0.80) | ABL1KCNH2BCRCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304171-A | Solid forms of pyrazine substituted nicotinamide, preparation and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-117304171-A | Solid forms of pyrazine substituted nicotinamide, preparation and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-20230322717-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230322717-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2023-10-12 | — | — | US | disclosed |
| CN-115413277-B | Solid forms of pyrazine substituted nicotinamide, preparation and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115413277-B | Solid forms of pyrazine substituted nicotinamide, preparation and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-115413277-A | Solid forms of pyrazine-substituted nicotinamide, their preparation and use | 深圳市塔吉瑞生物医药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115413277-A | Solid forms of pyrazine-substituted nicotinamide, their preparation and use | 深圳市塔吉瑞生物医药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| WO-2021213380-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | SHENZHEN TARGETRX, INC. (CN) | 2021-08-17 | — | — | US | disclosed |
| CN-110343092-B | (hetero) aryl amides for inhibiting protein kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2021-03-02 | — | — | CN | disclosed |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | SHENZHEN TARGETRX, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091462-B2 | (Hetero)arylamide compound for inhibiting protein kinase activity | MAP2K2, MAP2K5, MAP2K4 | ABL1 45/4885KCNH2 946/4885BCR 941/4885 |
| US-20200377473-A9 | (HETERO)ARYLAMIDE COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY | MAP2K2, MAP2K4, MAP2K5 | ABL1 40/4885KCNH2 974/4885BCR 947/4885 |
| US-20230322717-A1 | SOLID FORM OF PYRAZINE SUBSTITUTED NICOTINAMIDE, AND PREPARATION AND USE THEREOF | NAMPT, NADK, NNMT | ABL1 11/4885KCNH2 2391/4885BCR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.